Elevance Health reported Q2 results on July 15, and the Street's pre-earnings conviction has rapidly translated into fresh target raises — the question now is whether the stock at $426.79 can close the remaining gap to consensus.
The analyst response has been swift and unanimous in direction. TD Cowen lifted its target to $465 from $400 and Wells Fargo moved to $492 from $391, both on July 14, keeping Buy and Overweight ratings respectively. Truist raised to $475 from $450 the same day. That brings the consensus mean to roughly $441 — implying around 3% upside from current levels — and continues a trend that has seen virtually every firm move in the same direction across June and July. Morgan Stanley's Equal-Weight at $404 remains the lone dissenting voice, now well below where the stock actually trades. Bulls are pointing to Medicare Advantage margin expansion above 150 basis points in 2026 and improving D-SNP membership mix. Bears, less visible by the day, retain their concerns around Medicaid headwinds and the pace of EPS recovery toward $25.54 for the full year.
Options positioning reflects the post-earnings exhale. The put/call ratio has dropped sharply to 0.74, more than two standard deviations below its 20-day average of 0.80 — the most call-skewed reading in months. That marks a clear reversal from the neutral-to-cautious setup that prevailed in the weeks before the print, and suggests investors are now leaning into upside rather than hedging against downside. The shift is consistent with a stock that has risen nearly 6% over the past month and almost 2% on the week.
Short interest tells a supporting story. Shorts have been quietly reducing exposure throughout this run — short interest as a percentage of free float has fallen from around 3% to 2.76% over the past month, and the week-over-week decline of 4% confirms the direction of travel. Borrow costs at 0.40% are negligible, and availability is extraordinarily loose at nearly 7,900% — there are roughly 145 million shares available to borrow against a short position of barely 6 million. The lending market poses no friction whatsoever for either side.
Among close peers, the managed care group had a broadly constructive week. HUM gained 3.1%, CNC rose 3.9%, MOH added 3.7%, and CI climbed nearly 5.8% — ELV's 1.9% weekly gain lagged the group, which may partly reflect the stock having already run harder into the earnings date. UNH was the one notable laggard, slipping 0.7% on the week amid its own cost-trend concerns.
With Q2 now digested, the focus shifts to the tone of management guidance for the second half — specifically whether Medicaid margin commentary turns more constructive and whether Medicare Advantage enrollment momentum meets the expectations now embedded in a consensus target cluster between $450 and $492.
See the live data behind this article on ORTEX.
Open ELV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
